Cervical squamous intraepithelial neoplasia

This trial tests whether a single, outpatient treatment using low-thermal argon plasma can clear grade 2 cervical intraepithelial neoplasia (CIN2), a precancerous condition. Participants receive either the plasma treatment, a sham procedure, or standard active surveillance. The m…

This study tests whether a self-applied cream (5-fluorouracil) after a heat procedure (thermal ablation) can clear HPV better than a placebo cream in 140 women with HIV in Kenya. Participants will use the cream every two weeks for 24 weeks and be followed for 48 weeks total. The …

This study tests an experimental biologic, NWRD09, in women aged 18 to 65 with HPV16-positive cervical high-grade squamous intraepithelial lesions (HSIL), a precancerous condition. Participants receive four intramuscular injections over 12 weeks. The main goal is to see if the tr…

This trial tests an experimental vaccine called SYS6026 in people with high-grade cervical lesions caused by HPV type 16 or 18. The goal is to see if the vaccine can help the body clear the virus and reverse the lesions, potentially avoiding the need for surgery. Participants are…

This study tests whether a daily oral supplement containing green tea extract (EGCG), folic acid, vitamin B12, and hyaluronic acid can help women clear a persistent human papillomavirus (HPV) infection. HPV is a common virus that can cause cervical cancer if it stays in the body …

This early-stage trial tests an injection called BBM-C101 in 60 women with high-grade cervical precancer linked to HPV16 or HPV18. The goal is to see if the drug is safe and can shrink or eliminate abnormal cells, potentially offering a non-surgical alternative. Participants rece…

This study compares a non-invasive ultrasound treatment (HIFU) to standard observation for low-grade cervical lesions (LSIL/CIN1) in 180 pre-menopausal women. Most of these lesions go away on their own, but the trial aims to see if HIFU can speed up clearance of the lesion and th…

This phase 2 trial tests whether a single dose of the HPV vaccine (Gardasil-9) can reduce the infectivity of high-risk HPV in women aged 18-29 who already have the virus. Researchers will compare cervical samples from vaccinated and unvaccinated women at 6 months to see if vaccin…

This study tests a treatment called photodynamic therapy (PDT) for women with low-grade cervical precancer caused by HPV types 16 or 18. A photosensitizing cream is applied to the cervix, then activated with light to destroy abnormal cells. The trial will compare 225 women who re…

This study compares a light-activated gel treatment (ALA-PDT) to standard surgery (LEEP) for women with high-grade cervical precancer (HSIL/CIN2). About 560 women will receive either the gel plus red light therapy or surgery. The goal is to see if the gel treatment works as well …

This study tests whether the HPV vaccine can prevent the return of high-grade squamous intraepithelial lesions (HSIL) in people who have already been treated for them. About 984 adults aged 18–55 with HPV-related HSIL of the cervix, vulva, vagina, penis, or anus will receive eith…